精准细胞免疫治疗中肿瘤新抗原相关研究进展

如何通过细胞表面抗原使免疫系统区分正常细胞和癌细胞是肿瘤细胞免疫治疗的关键。最新的技术使人们了解到，由于肿瘤细胞突变产生新的表位肽，继而引起患者的特异性免疫应答；并且最新研究表明，这种肿瘤新抗原（neoantigens）的识别将成为临床免疫治疗的重要突破点。相关结果表明，在癌症免疫治疗中，肿瘤新抗原可以作为一种生物标志物，开发并增强针对这类抗原选择性T细胞的反应性，为新型免疫治疗带来希望。精准细胞免疫治疗(precision cell immunotherapy treatment，PCIT)是通过高通量基因测序及大数据分析，获得针对癌细胞特异性新型抗原和高效应的精准T细胞(precision T cell for neoantigen，PNA-T)，进而富集 PNA-T对肿瘤患者进行精准细胞免疫治疗。

The research progress of neoantigens in precise cellular immunotherapy

How to use the cell surface antigen to distinguish the immune system from normal cells and cancer cells is the key to tumor cell immunotherapy.The latest technology has led people to understand that the mutation of tumor cells produces new epitope peptides，which in turn cause specific immune responses in patients,and the latest research shows that the identification of neoantigens of this tumor will become important for clinical immunotherapy breaking point.The results show that，in cancer immunotherapy，tumor neoantigens can be used as a biomarker to develop and enhance the reactivity against such antigen-selective T cells，providing hope for new immunotherapy.Precision cell immunotherapy (PCIT) uses high-throughput gene sequencing and big data analysis to obtain precise T cells for neoplasm (PNA-T)，and then enrich PNA-T for precise cellular immunotherapy of cancer patients.